Rhythm Biosciences (ASX: RHY) has secured a strategic partnership with CancerIQ that provides immediate access to over 65 US health systems and over 345 clinics. The Rhythm Biosciences CancerIQ partnership enables the diagnostic company to bypass the traditional sales force model, embedding its geneType™ Cancer Risk Assessment directly into clinical workflows serving millions of Americans.
This is a distribution partnership with material commercial implications. Rather than spending years building hospital relationships one-by-one, Rhythm gains day-one access to an established clinical infrastructure already deployed across major US healthcare networks. The partnership creates a clear pathway to recurring test revenues without the cost and complexity of building a direct sales force.
CancerIQ’s cloud-based platform helps hospitals and healthcare providers scale their high-risk genetic testing programmes through workflow optimisation and automated test ordering. By integrating geneType™ within this existing infrastructure, Rhythm significantly de-risks its US commercialisation strategy whilst reducing capital requirements in the competitive cancer diagnostics market.
CEO Commentary
“This partnership transforms our US market entry strategy. Instead of building clinic relationships one-by-one, we now have immediate access to hundreds of clinics through a proven platform that’s already trusted by leading health systems. More importantly, we’re embedded in the clinical workflow where cancer risk decisions are made daily – this is exactly how successful diagnostic tests achieve sustainable, recurring revenues,” said Dr. David Atkins, Chief Executive Officer and Managing Director.
How the CancerIQ platform creates recurring revenue potential
The partnership establishes a revenue model aligned with clinical workflows rather than one-off sales. Each geneType™ test ordered through the CancerIQ platform generates revenue for Rhythm, with the embedded workflow designed to support repeat test volumes as patients move through cancer screening pathways.
CancerIQ’s ordering wizard reduces administrative friction that typically slows clinical adoption. The platform enables healthcare providers to seamlessly order geneType™ tests with automated patient data population, eliminating paperwork barriers whilst improving clinical efficiency. This automation creates lower-friction adoption pathways that typically accelerate commercial uptake.
The workflow integration matters because it positions testing within ongoing patient care cycles. As patients return for follow-up screenings or move through prevention planning, the platform supports repeat testing without requiring additional relationship building or sales intervention. This embedded approach provides a foundation for long-term commercial traction in the US market.
Three key benefits of CancerIQ’s ordering wizard:
- Reduces administrative friction that typically slows test adoption
- Improves clinical efficiency through automated data population
- Supports scalable commercial rollout across US healthcare systems
Understanding polygenic risk assessment in cancer screening
Traditional hereditary testing looks for rare, high-impact genetic mutations that affect a small subset of patients. These tests identify individuals carrying specific genes that significantly increase cancer risk, but they only apply to a limited patient population with strong family histories or known genetic predispositions.
Polygenic risk assessment takes a different approach. Rather than searching for rare mutations, geneType™ evaluates the combined influence of common genetic variants together with clinical and lifestyle factors to estimate a patient’s overall baseline risk. The test integrates this genetic data with clinical factors and modifiable lifestyle inputs to shape overall disease risk profiles.
This multifactor risk modelling expands the addressable market beyond the small percentage with hereditary mutations to broader population-level risk assessment. Whilst hereditary testing answers “Do I have a high-risk gene?”, polygenic testing addresses “What is my overall risk based on my unique genetic profile and health factors?”
Within the CancerIQ platform, geneType™ expands the menu of options by adding polygenic and multifactor risk modelling alongside the hereditary and multi-gene testing solutions already available through CancerIQ. The technology stands out for its integrated approach, combining genetic, clinical, and modifiable risk inputs into a single risk model designed to support personalised screening and prevention planning.
| Testing Approach | What It Identifies | Patient Population | geneType Advantage |
|---|---|---|---|
| Hereditary Testing | Rare high-impact mutations | Small subset with family history | — |
| Polygenic Risk (geneType) | Combined common variants + clinical factors | Broader population | Personalised baseline risk assessment |
CancerIQ’s established health system network validates platform credibility
The CancerIQ platform is already trusted by major US healthcare institutions, providing third-party validation that reduces Rhythm’s execution risk. These are not small clinics but established health systems representing significant US healthcare infrastructure.
Existing health system partners include:
- Advocate Health
- Fred Hutch Cancer Center
- Mount Sinai Health System
- University of Pittsburgh Medical Center
Recent enterprise-wide master service agreements:
- Ardent Health
- Ascension
- CommonSpirit Health
- Corewell Health
- Hackensack Meridian Health
These recent enterprise agreements reflect the platform’s strong penetration in key US healthcare regions. The partnerships demonstrate clinical utility and market acceptance that Rhythm inherits through the integration, bypassing years of relationship building and capital investment that would otherwise be required to establish similar market access independently.
CancerIQ Leadership Perspective
“Our mission is to help health systems scale access to genomics and innovation across oncology by embedding risk assessment directly into clinical workflows. Integrating geneType™ into the CancerIQ platform expands our ability to identify cancer risk earlier and at a population level, extending beyond traditional hereditary testing. This partnership reinforces CancerIQ’s role as a scalable infrastructure layer for precision diagnostics, enabling providers to operationalise emerging technologies within a single, unified platform,” commented Feyi Ayodele, Founder and Chief Executive Officer of CancerIQ.
What’s next for Rhythm’s US commercialisation pathway
The partnership aligns with Rhythm’s broader strategy to embed geneType™ into established clinical platforms that support scalable deployment across large healthcare networks. The integration model enables efficient market access whilst leveraging CancerIQ’s existing provider relationships, workflow infrastructure, and data capabilities.
The US remains one of the world’s largest precision medicine and preventative healthcare markets. Growing demand for personalised risk assessment tools strengthens the commercial case for geneType™ as healthcare providers increasingly seek comprehensive genomic risk assessment solutions.
geneType™’s multi-disease assessment capabilities position it to capture this demand across multiple conditions. The platform provides risk assessments for breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma, delivered through healthcare providers and genetic counsellors with appropriate clinical oversight.
The partnership model itself is potentially replicable. Success with CancerIQ demonstrates a commercialisation template that could extend to other platform partnerships or geographic markets, creating multiple pathways for commercial expansion without proportional increases in capital requirements or sales infrastructure.
Want more Biotech breakthroughs before the market reacts?
Rhythm Biosciences’ distribution partnership with CancerIQ demonstrates how strategic clinical integrations can accelerate US market entry without the capital intensity of traditional commercialisation models. For investors tracking the Biotech and Healthcare sectors, these structural shifts in diagnostic company strategy often signal material developments before broader market recognition occurs.
The StockWire X Big News Blasts service delivers breaking ASX news across Technology, Biotech, Healthcare, Finance, and Industrials—completely FREE. With comprehensive analysis trusted by over 20,000 active subscribers, the alerts provide context on emerging partnerships, regulatory milestones, and commercial developments that move share prices. Click the “Free Alerts” button in the menu to join thousands of investors who receive Big News Blasts directly to their inbox.